GlassScriptPhysician profile
Praneeth Kudaravalli
NPI 1629495973
$6,173.16
in general payments reported to CMS, 2019-2025
18 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,231 · 2023: $305 · 2024: $4,314 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005 · Travel and Lodging: $1,687 · Grant: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.41 |
| Travel and Lodging | $1,687.19 |
| Grant | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,931.78 | 2023-2024 | Axios, Exalt Model D |
| Cook Incorporated | $1,250.00 | 2024 | |
| Wilson Cook Medical Incorporated | $950.07 | 2022 | |
| Abbvie INC. | $373.92 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.48 | 2023 | Xifaxan |
| Cook Medical LLC | $107.91 | 2025 | Echotip Insight |
| Alkermes, INC. | $97.65 | 2024 | Lybalvi |
| Laborie Medical Technologies Corp. | $97.44 | 2022 | |
| Qol Medical, LLC | $59.57 | 2024 | Sucraid |
| Genzyme Corporation | $32.95 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.45 | 2024 | Eohilia |
| Conmed Corporation | $25.09 | 2024 | Conmed Hemostasis, Conmed Biliary |
| Biocon Biologics INC | $20.69 | 2025 | Yesintek |
| Janssen Biotech, INC. | $20.04 | 2025 | Tremfya |
| Aimmune Therapeutics, INC. | $16.22 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $15.47 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $15.29 | 2025 | Voquezna |
| Lilly USA, LLC | $14.14 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Praneeth Kudaravalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.